CompletedPhase 2NCT01803035
A Phase II Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 in Impetigo
Studying Bullous impetigo
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Lytix Biopharma AS
- Principal Investigator
- Daisy M Blanco, MDInstitute of Dermatology and Skin Surgery, Dr. Hubert Bogaert Diaz, Santo Domingo
- Intervention
- LTX-109 1 %(drug)
- Enrollment
- 210 enrolled
- Eligibility
- 2 years · All sexes
- Timeline
- 2013 – 2014
Study locations (2)
- Dr. Robert Reid Cabral Children Hospital, Santo Domingo, Dominican Republic
- Institute of Dermatology and and Skin Surgery Dr. Hubert Bogaert Diaz, Santo Domingo, Dominican Republic
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01803035 on ClinicalTrials.gov